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Mice which survive infection with Listeria monocytogenes are highly resistant 
to reinfection and specifically hypersensitive to Listeria antigens (1). The resist- 
ance and the accompanying state of delayed-type hypersensitivity can both be 
transferred  to normal  recipients  with immune  lymphoid ceils obtained from 
actively infected donors  (2).  Since neither of these immunological  modalities 
can be transferred with immune serum (1, 2, 3), it is a useful model for studying 
the  action  of  anti-lymphocyte globulin  on  an  immune  mechanism  which  is 
mediated by activated lymphoid cells to the apparent exclusion of humoral anti- 
body. 
According to current dogma,  cell-mediated  mechanisms  of immunity  are 
initiated  by uncommitted lymphoid ceils  which transform, divide,  and differ- 
entiatc  to form immunologicaUy committed cells.  In this  circumstance, anti- 
lymphocyte gioblflin  (ALG) would have two potential  targets  against  which to 
act.  The  first  would  consist  of  the  immunocompetent cells  which  become  engaged 
early  in  the  infection,  and the second would be the immunologicaIly committed 
progeny  of  the  first.  The former  belong  to  the  afferent  and  the  latter  to  the  effer- 
ent  limb  of  the  arc.  The  cells  which  were  shown  in  the  accompanying paper  (2)  to 
protect  normal recipients  against  a lethal  challenge  infection  and render them 
hypersensitive  to  Listeria antigens  are obviously committed cells.  The present 
paper describes  the action  of  ALG  on this  cell  type.  The effect  of  ALG  on the 
afferent  arc,  and  its  influence  on  delayed-type hypersensitivity,  will  be  reported 
separately. 
Materials and Methods 
GeneraL--The  animals,  organisms,  method  of immunization,  preparation  of spleen cell 
suspensions,  and  measurement  of anti-Liasria resistance were described  in  the  preceding 
paper (2). 
A~i-Lympkocyte GlobuHn.--An anti-serum against mouse lymphoid cells was prepared in 
rabbits by the intravenous injection of 109 living thymocytes, given on two occasions at an 
interval of 2 wk. Begdnnlng  I  wk later, the animals were bled twice weekly. The serum col- 
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letted over a period of 4 wk was pooled and processed. Bleedings were continued for a further 
4 months without further immunization. This serum was also pooled to make a second batch 
of antiserum. The two batches of pooled serum were brought to 37% saturation with am- 
monium sulfate. The precipitate was redissolved in saline and absorbed with mouse RBC to 
remove residual hemagglutinins. The globulins were reprecipitated and washed twice with 37% 
saturated  ammonium sulfate. They were then dissolved in, and dialyzed against a phosphate 
buffer (0.01 M, pH 7.3) prior to separation on a 2.5 X 45 cm column of DEAE-ceUulose  which 
had been equilibrated with the same buffer. The proteins which were not retained  on the 
column (ALG) were lyophilized and redissolved in saline to a concentration of 9.75 mg/ml. 
The final product was devoid of hemagglutinins and gave a single precipitin line which cor- 
responded to IgG by immunoeleetrophoresis.  Serum from unimmunized rabbits was processed 
in the same way to obtain a preparation of normal rabbit globulin (NRG) containing 9.0 mg 
protein/ml. 
Titration  of  Lympkaggbutinating Activity.--Lymphagglutinating  activity  was  assayed 
against mouse thymocytes and thoracic duct lymphocytes which had been washed and sus- 
pended in basic saline solution (BSS) at a concentration of 2 X  107 per ml. These were added 
to equal volumes of serial dilutions of NRG or ALG. The mixtures, in a volume of 0.4 ml in 
12 X 75 mm tubes, were incubated for 30 rain at 37°C in a water bath oscillating at 120 
epm. After standing for 1 hr at 4°C, they were gently resuspended and examined microscopi- 
cally for evidence of agglutination. 
Assay of Lymphocytolysis.--The eytotoxicity of ALG was assayed only in the presence and 
absence of fresh, normal mouse serum. Serial dilutions of NRG and ALG in Hanks' BSS were 
prepared and added to mouse thymocytes suspended in 20% normal mouse serum at a'con- 
centration of 2 X  l0  T per ml. The suspensions were let stand for 1 hr at 4°C and were then 
incubated without shaking at 37°C for 50 rain. At the end of incubation, samples from each 
tube were diluted in trypan blue (0.05%) and examined after 5 rain for evidence of nuclear 
staining. 
~S~TS 
Activity of ALG in Vitro.--The two preparations of ALG used in the present 
study showed comparable lymphaggulutinating activity. Except for a  prozone 
effect,  high concentration of each  preparation gave massive  agglutination of 
thymocytes and thoracic duct lymphocytes, and sharp agglutinating end points 
at a  dilution of 1:128. When RBC were  added artificially to a  suspension of 
thymocytes in the presence of ALG, the former remained randomly distributed, 
while the thymocytes became aggregated into clumps devoid of RBC. 
When tested for cytotoxicity against thymocytes, both NRG and ALG caused 
considerable cell death  (approximately 70%  under the conditions of  test)  at 
protein concentration of less than 0.3 mg/ml. In the presence of a constant con- 
centration (20 %) of fresh mouse serum, however, the anti-lymphocyte globulin 
showed no cytotoxic activity at the highest concentration (4.9 mg protein/ml). 
It is presumed, therefore, that the ALG used in these studies was not cytotoxic 
for mouse thymocytes in the presece  of  whatever complement is  available in 
fresh normal mouse serum. 
Effect of ALG on the Passive Transfer of Antibacterial Resistance with Immune 
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donors on the 7th day after an intravenous injection of 8.6 X  10  ~  viable List~'ia. 
Cells from unimmunlzed donors were prepared at the same time. After the third 
washing, the cells were suspended in 1% fetal calf serum (FCS) at a concentra- 
tion of 4 X  10S/ml. The immune cells were divided into two parts to which ALG 
or NRG were added in doses of 0.97  and 0.90 nag protein/100 million cells. 
Normal cells were treated with NRG only. The cell suspensions were injected 
immediately into the tail vein of normal recipients which had been challenged 
30 rain previously with 2.1 X  1@ (4 L950) viable List~ia. Five injected animals 
which did not receive cells were killed at this time to establish the initial levels 
of bacterial implantation in spleen and liver. Bacterial counts were made after 
24 and 48 hr on the spleens and livers of five mice from each of the three groups. 
Fig. 1 illustrates the effect of ALG on the transfer of anti-Lisleria immunity 
with lymphoid cells  obtained from the spleens of 7-day immune donors.  It 
shows that a small dose, equivalent to the specific antibody contained in 0.97 
mg protein, was effective in abolishing the protection conferred by immune 
lymphoid cells which had been treated with NRG. 
In the foregoing experiment, the transferred lymphoid cells were inactivated 
by exposure to ALG in vitro. They were equally sensitive to inactivation in vivo. 
When given intravenously to recipients before, or soon after cell  transfer, a 
similar dose of ALG (0.97 rag/mouse) totally inhibited the protective activity of 
immune lymphoid cells. The results in Fig. 2 show that heat-inactivation of cells 
and an injection of ALG given 1 hr alter cell transfer were equally effective in 
abolishing the immunity conferred with 7-day immune lymphoid cells (10 s cells 
of 86% viability). The effect of treatment of recipients with ALG be/ore cell 
transfer is described in later experiments. 
Assay of Antilymphocyte Activity in Vivo.--Equal volumes of a  serial 2-fold 
dilution of ALG were added to five aliquots of a pooled suspension of filtered 
spleen cells prepared from 7-day immune mice. The additions were made after 
the cells and dilutions of ALG had been chilled to 2°C. As each addition was 
made, it was injected ito groups of I0 mice which had received an intravenous 
challenge dose of Listeria (1.9 X  104) 15 mln previously. The cells were injected 
in a volume of 0.5 mi containing 10  s spleen cells (64% viability) and amounts of 
ALG which ranged from 2.0 to 0.1 rag protein. A group of control mice received 
the same number of immune spleen cells which had been treated with NRG at 
the highest protein concentration (2.0 rag/10  s cells). The initial level of bacterial 
implantation in spleens and livers was determined in mice which did not receive 
cells. 
The effect of varying doses of ALG on the protective activity of 10  s Listeria- 
immune spleen cells is depicted in Fig. 3. All but the lowest dose of ALG (0.1 
rag/10  s cells) produced a total suppression of protective activity in both liver 
and spleen. Only the liver, which is slower to respond (2), showed clear evidence 
that the lowest dose of ALG was subinhibitory. 996  ANTI-LYMPHOCYTE  GLOBULIN  AND  RESISTANCE  TO  INFECTION 
Persistence of ALG Activity in  Vivo.--The neutralizing effect of ALG on pas- 
sive protection against challenge with L.  monocytogenes was used to study the 
persistence of anti-lymphocyte activity in vivo. 
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FIG. 1. Growth curves of L. monocytogenes in livers and spleens of mice which were protected 
passively with normal or L/steria;immune spleen cell suspensions. The cells were treated  with 
ALG or NRG immediately prior to transfer.  Means of 5. 
At intervals from 0-24 hr prior to the transfer of immune spleen cells, groups 
of prospective recipients were injected intravenously with 0.1 ml ALG contain- 
ing 0.97 nag protein. At zero time, all mice were passively immunized with a pool 
of filtered  spleen  ceUs prepared  from 7-day immune  donors.  Each mouse re- G.  B.  MACKANESS  AND  WILLIAM  C.  HILL  997 
ceived the challenge inoculum of L. monocytogenes (8.6  X  l0  s)  admixed with 
2.1  X  l0  s spleen cells of 78% viability. The initial implantation of Lisleria in 
spleens and livers was determined in a group of 5 untreated mice which were 
sacrificed 30 rain after injection.  Spleen and liver counts were performed on 
mice of all groups after an interval of 48 hr. 
Fig. 4 shows that anti-lymphocyte activity persisted in the blood for at least 
24 hr after an intravenous injection of ALG (0.97 mg total protein). In compari- 
son with untreated mice, those receiving ALG between 0-3 hr before cell trans- 
0  .I 
u. 
¢) 
o" 
4 
7  6 
LIVER 
/2__i 
"-cells  4 
!  2 
24 
Hours 
/  /° 
-----Z__o 
! 
24 
FiG. 2. Growth  of L. monocytogenes in livers and spleens  of mice  which  had received  living  or 
heat-killed spleen cells from Listeria-immune donors. One hr after transfer the recipients of 
living cells were injected intravenously with either ALG or NRG (approx. 1.0 rag/mouse). 
Means of 5. 
fer showed what must be regarded as complete suppression of passively acquired 
resistance. The inhibitory effect was somewhat less in animals which received 
their injections of ALG at intervals ranging from 6-24 hr before transfer. The 
spleens of these animals contained 100-fold fewer organisms than were found in 
animals treated with ALG at the time of transfer, but 10,000-fold more than 
were present in untreated controls (Fig. 4, C). The partial loss of anti-lympho- 
cyte activity in the blood of mice treated 6 or more hr prior to cell transfer may 
have been due to absorption of antibody by specifically reactive cells encoun- 
tered in the circulation, to equilibration of antibody between intra- and extra- 
vascular fluids, or to its absorption by lymphoid cells outside the circulation. 
The Accessibility of Immune Lympkoid  Cells in Vivo.--Fluorescent  antibody 998  ANTI-LYMPHOCYTE  GLOBULIN AND RESISTANCE TO  INFECTION 
studies (4) have suggested that immunoglobulin molecules penetrate poorly into 
lymphoreticular tissues,  so that lymphoid cells within spleen and lymph nodes 
are not easily accessible to the action of ALG. In this circumstance, it might be 
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Fro. 3. Growth curves of L. monocytogenes in the avers and spleens of mice which were 
protected  passively with untreated  immune spleen cells (0.0) or with immune cells treated 
with NRG (2.0 mg.) or ALG in doses ranging from 2.0 to 0.1 rag. Each mouse received 10  s 
spleen cells mixed with ALG or NRG immediately prior to transfer. Means of 5. 
difficult  to  neutralize  immune  lymphoid  cells  within  the  spleens  of immune 
donors. The fact that a  substantial level of anti-lymphocyte activity persisted 
in the circulation for 24 hr after the injection of 1 rag ALG signifies that the total G.  B.  MACKANESS AND WILLIAM C,  HILL  999 
mass of lymphoid cells in the body is insufficient to absorb this dose of ALG or 
that ALG does not have access to all lymphoid cells in vivo. 
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FIG. 4. Growth of L. mo,ocytog~es  in livers and spleens of untreated mice (C) and mice 
which received a single intravenous injection of ALG (1.0 rag) at varying times (0 to --24 
hr) before the injection of 2.0 X  108 immune spleen cells. Means of 5. 
The present model offers an opportunity to examine this question. If ALG 
penetrates into lymphoid tissues,  the immunologically committed cells in the 
spleen could be inactivated in situ. In the first attempt to investigate this ques- 
tion donor mice were injected intravenously with ALG (4.9 mg total protein) or 
NRG (4.5 mg total protein) on the 6th day of the immunizing infection. 24 hr 1000  ANTI-LYMPHOCYTE  GLOBULIN  AND  RESISTANCE  TO  INFECTION 
later, both groups of donors were exsanguinated to remove as much of the cir- 
culating ALG as possible. Spleen cell suspensions were then prepared and trans- 
ferred, together with the challenge inoculum of Lisleria, to two groups of normal 
recipients. Normal cells were given to a group of controls. The recipients of cells 
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FIC. 5. Growth curves of L. monocytogenes in livers and spleens of mice which had received 
spleen cells from normal donors (A) or immune donors which had been injected 24 hr pre- 
viously with 5.0 mg of ALG (O) or NRG (O). Means of 5. 
from ALG-treated donors were not protected even though they received a larger 
number of viable spleen cells (6.1  X  107) than did the recipients of NRG-treated 
donors (4.7  X  107). 
Since the foregoing result could not be reconciled with subsequent observa- 
tions,  the experiment was repeated with one difference. After the spleens had 
been removed from exsanguinated donors, they were sectioned into 5 or 6 parts G.  B.  MACKANESS  AND  WILLIAM  C.  HILL  I001 
and suspended in 100 ml of BSS at 4°C. Mter 30 rain, they were again washed in 
BSS before being dissociated by screening through a 50-mesh grid. They were 
then treated in the usual way. The washing of the sliced spleens was done in the 
hope that unbound antibody would be leached from the tissue before it could 
attach to cells during dissociation. The results, recorded in Fig. 5,  show that 
immune lymphoid cells from ALG-treated donors were still highly active when 
transferred to recipients. In this experiment, the recipients of cells from ALG- 
treated and NRG-treated donors were injected with 1.9 X  l0  s and 1.3 X  l0 s 
viable spleen cells, respectively. The relatively low level of passive protection 
obtained with this dose of cells is attributed to the small infecting dose (240 
viable organisms) which was used to immunize the donors. 
The Question of Antimacrophage Activity in ALG 
All of the preceding observations could be taken to indicate that ALG inter- 
feres with passive immunization through its capacity to kill or neutralize the 
activity of immune lymphoid cells. The findings would be as easily explained, 
however, if ALG were active against the macrophages of the recipients rather 
than the lymphoid cells of the donor. Were it capable of preventing phagocyto- 
sis or interfering with the activation of host phagocytes, the ALG-treated recip- 
ient might fail to benefit from the protection normally conferred with immune 
lymphoid cells. To examine this possibility, a number of experiments were per- 
formed. In the first experiment, immune lymphoid cells were treated with ALG 
in vitro and were then washed exhaustively to remove excess  ALG prior to 
injection into normal recipients. 
Transfer with Washed Cells.--Filtered  spleen ceils from 8-day immune mice 
were washed 3 times and brought to a concentration of 4.3  X  10S/ml in 1% 
FCS.  At this stage, a  dye-exclusion test showed that 78%  of the cells  were 
viable. They were divided into two parts, one of which was treated with NRG 
(1.8  nag protein/10  s cells)  and the other with ALG (1.9  rag/10  s cells).  Mter 
these additions, the ceils were let stand for 1 hr at 4°C. The cell suspensions 
were then washed 3 times in 100 ml of 1% FCS in BSS. They were finally sus- 
pended at a concentration of 4 X  10S/ml in a medium containing approximately 
2 X  104 viable Listeria/rnl.  At this stage, the NRG and ALG treated cells were 
respectively 69 and 79% viable and contained 1.7 X  1@ and 1.2 X  104 viable 
Listeria per ml as determined by plate count. They were injected intravenously 
into two groups of normal recipients in a volume of 0.5 nil. Spleen and liver 
counts were performed on 5 mice from each group after 15 rain and again after 
24 and 48 hr. 
The  results  of  the  foregoing experiment  showed  that  ALG-treated  cells, 
though viable at the time of transfer, were devoid of protective  activity in 
recipients (Fig. 6). It must be reasoned that extensive washing has removed all 
but trace amounts of free antibody from the cell. Since it is unlikely that the 1002  ANTI-LYMPHOCYTE  GLOBULIN  AND  RESISTANCE  TO  INFECTION 
macrophages  of  recipient  mice  would  be  damaged  by  antibody  bound  to 
lymphoid cells, it is concluded that ALG owes its suppressive effect to its action 
on donor cells. 
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Means of 5. 
Macrophage Agglulinating  Activity  of  ALG.--As  a  further  test  for  anti- 
macrophage activity in the two ALG preparations used in these experiments, 
they were assayed for agglutinating activity against normal peritoneal macro- 
phages. The test posed a  problem, for mouse macrophages agglutinate spon- 
taneously under the conditions usually employed for assaying leukagglutinating 
activity. This difficulty was largely overcome by performing the tests at 2°C. 
Ceils were harvested from the peritoneal cavities of 10 normal mice. They G.  B.  MACKANESS  AND  WILLIAM C.  HILL  1003 
were washed twice and suspended in BSS at a  concentration of 2  X  107/ml. 
Thymus glands from the same animals were used to prepare a washed suspen- 
sion of thymocytes at the same density. The preparations of ALG (9.7 mg/ml) 
and NRG (9.0 mg/ml) were serially diluted and added to equal volumes (0.2 
ml)  of the  two  cells suspensions  in  12  X  75 mm  tubes.  The mixtures were 
shaken at 120 cpm in an ice water bath at 2°C for 60 min. Samples from each 
tube were then examined in hemocytometer chambers for evidence of agglutina- 
tion. 
Table I  shows  a  titration of the thymocyte and macrophage-agglutinating 
activities of the second of the two ALG preparations used in the present experi- 
ments.  A  minor  amount  of  clumping,  affecting less  than  10%  of  the  cells, 
occurred in all tubes containing peritoneal macrophages, but no agglutination 
TABLE I 
Assay of Leukagglutinating  Actidty  of ALG against Mouse  Thyraocytes and  Peritoneal 
Macrophages 
Antigen 
Peritoneal 
cells 
Thymocytes 
Anti- 
serum 
NRG 
ALG 
NRG 
ALG 
1:2 
::£:: 
-4- 
++++ 
Dilutions  of  ALG (9.75  mg/ml) and  NRG  (9.0  mg/ml) 
1:4 
4- 
-4- 
++++ 
1:8  1:16 
-4-  .4_ 
"4-  :::1:: 
B  m 
++++++++ 
1:32 
.4_ 
"4- 
+++ 
1:64 
::k 
.4- 
++ 
1:128 
.-I- 
.4- 
Control 
.q- 
q- 
++++,  Massive agglutination. 
4-, Occasional clumps and many pairs. 
--, No associated  cells. 
which  could be attributed to specific antibody.  It should be noted that  the 
agglutinin titer against thymocytes at 2°C was one tube less than in tests per- 
formed at 37°C. 
The exact composition of the peritoneal ceils used in the agglutination test is 
unknown. Apart from mature macrophages, which constituted 62 % of the cells 
present, an unknown percentage of the smaller cells in the peritoneal cavity of 
the mouse may also be macrophages at  an immature stage  of development. 
The true lymphocyte content may thus be quite small. Since the antiserum was 
prepared against  thymocytes and  shown  to be  active  against  thoracic duct 
lymphocytes, the absence of agglutination among mixed cells of the peritoneal 
cavity may mean that circulating lymphocytes of the type found in thoracic 
duct lymph are not well represented in  the  normal  peritoneal cavity of the 
mouse. 
The absence of macrophage agglutinating activity points again to the conclu- 1004  ANTI-LYMPHOCYTE GLOBULIN AND  RESISTANCE  TO  INFECTION 
sion  that ALG interferes with the passive  transfer of immunity  through its 
effect on immune lymphoid cells.  Further evidence of this is contained in the 
following experiment. 
The Effect of ALG on Established Immunity in Intact Mice.--Mter a sublethal 
infection with L. monocytogenes the host's macrophages become conspicuously, 
but nonspecifically, bactericidal. At this early stage of convalescence, the host 
is absolutely resistant to a Listeria  challenge by virtue of the activated macro- 
phages present in the tissues (1). If ALG is devoid of anti-macrophage activity, 
it would not be expected to influence host resistance at this stage of convales- 
cence. 
Surviving mice which had been immunized 7 days earlier with a  relatively 
large immunizing dose of Listeria  (4.5  X  103) were injected intravenously with 
large doses of ALG or NRG (5.0 mg protein). They were challenged with L. 
monocytogenes (5.1  X  104 =  10 LDs0) 24 hr later. A group of unimmunized con- 
trois were challenged at the same time. After 15 rain, and at 24 and 48 hr, 5 
mice  from  each  group  were  used  for  estimating  viable  bacterial  counts  in 
spleen and liver. 
Fig.  7  shows  that ALG had little effect on host resistance when given to 
actively immunized mice at the height of their response to a sublethal infec- 
tion. Since resistance at this time is due to the presence of activated macro- 
phages in the host, it follows that ALG does not possess any marked capacity 
to interfere with the physiological activity of macrophages in vivo. The dose 
of ALG used in this experiment was 40 times greater than the amount needed 
to abolish the activity in 10  s spleen cells (Fig. 3). It seems, therefore, that resist- 
ance at this stage  of convalescence is vested in cells which are inaccessible or 
are unaffected by ALG. 
Effect of Antilymphocyte  Globulin upon the Recall of A nti-Listeria  Resistance.- 
Later in convalescence, Listeria-infected  mice enter a second phase of resistance 
to reinfection (1). It lasts for several weeks, during which the animal displays 
hypersensitivity to Listeria  antigens; and resistance to reinfection is character- 
ized by a short period of latency before the host's macrophages become reac- 
tivated to provide a mechanism for eliminating the parasite. The effect of anti- 
lymphocyte serum on this second, or reactivation phase, of acquired cellular 
resistance was investigated. A  preliminary experiment indicated that a single 
injection of ALG had little effect upon the capacity of previously infected mice 
to show the characteristic recall of acquired resistance. This finding was con- 
sistent with the observation (Fig.  5)  that  a  single injection of ALG did not 
neutralize committed cells within the spleens of immune donors. It was reasoned 
that more protracted treatment with ALG might influence residual immunity 
if the ceils responsible beong to a  recirculating pool.  Migration should bring 
them in contact with ALG sooner or later. 
Animals were immunized intravenously with 1.0  X  10  3 viable L. monocyto- G.  B.  MACKANESS  AND  WILLIAM  C.  HILL  1005 
genes. On days 21 and 28, haft of the immunized mice were injected subcutane- 
ously with 0.5 ml of ALG (4.9 mg protein); the remainder received a comparable 
dose of NRG (4.5 mg protein).  Two groups of normal mice were treated sim- 
ilarly. Three days after the second injection,  all mice were challenged with L. 
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FxG. 7. Growth curves of L. monocytoganes in normal (A) and reinfected mice which were 
treated on day 6 of the primary infection with 5 mg of NRG (O) or ALG (O) and challenged 
24 hr later with 40 Lu~o's  of virulent Listeria. 
monocytogenes (9.5  X  103  =  2 LDs0). After 15 min, and again at 24 and 48 hr, 
five mice from each group were used for viable counts on spleen and liver. 
Fig.  8 shows that  10 days of treatment with approximately 10 mg of ALG 
had a marked depressive effect on the capacity of convalescent mice to show 
the  characteristic  recall  of acquired  resistance  which  normally exists in  pre- 
viously infected mice. The effect was more marked in the liver, but the bacterial 1006  ANTI-LYMPHOCYTE  GLOBULIN  AND  RESISTANCE  TO  INFECTION 
growth pattern in the spleen showed that a low level of residual reactivity still 
persisted in the ALG-treated animals.  8[ 
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after the primary infection. At 10 and 4 days prior to reinfection the animals were injected 
subcutaneously with NRG or ALG (5.0 rag). Means of 5. 
DISCUSSION 
Previous studies have shown that the ultimate expression of resistance  against 
Listeria  monocytogenes and  other  facultative  intracellnlar  parasites  depends 
upon  the  activation  of  host  macrophages  (1).  Although  an  immunological 
mechanism has been clearly implicated (5), its nature could only be deduced 
from some circumstantial evidence which seemed to indicate that delayed-type 
hypersensitivity was somehow involved (6).  Since the latter is thought to be 
mediated by immunologically committed lymphoid cells (3), and is susceptible G.  B.  MACKANESS  AND  WILLIAM  C.  HILL  1007 
to suppression by anti-lymphocyte serum (7), it is logical to apply this reagent 
to an analysis of the mechanisms which underlie the phenomenon of acquired 
cellular resistance to infectious disease. 
Gaugas and Rees (8) have already shown that anti-lymphocyte  serum impairs 
the development of resistance to two classical intracellular bacterial infections. 
Chronic treatment of mice shortened the survival time of tuberculous mice and 
enhanced the multiplication of Mycobacterium lepraemurium in mouse tissues. 
But anti-lymphocyte serum also interferes with antibody production (9,  10, 
11), making it difficult to draw conclusions in regard to mechanism from experi- 
ments on actively immunized animals. 
It was shown in the previous paper (2)  that resistance and hypersensitivity 
to  Listeria are  transferred  concurrently with  immune  lymphoid cells  from 
actively infected donors. Before concluding that delayed-type hypersensitivity 
and acquired cellular resistance are outward expressions of a  common immu- 
nological pathway, it was necessary to exclude the possibility that suspensions 
of immune spleen cells  are heavily contaminated with monocyte precursors, 
and that these are the cells which provide a protective mechanism for recipient 
animals.  It  could be  reasoned  that  resistance  to  infection and  the  state  of 
delayed-type hypersensitivity are independent phenomena, one resulting from 
induced changes in  cells  of  the monocyte-macrophage series,  and  the  other 
from immunological commitment on the part of cells belonging to the lymphoid 
series. The specificity of ALG provides the means to resolve this question. 
It was shown that the absolute protection which can be adoptively conferred 
with immune spleen cells is totally ablated by the IgG fraction of an antiserum 
which was raised against mouse thymocytes but showed equal agglutinating 
activity against thoracic duct lymphocytes. Four lines of evidence indicate that 
it was devoid of activity against mouse macrophages. (a) ALG did not agglu- 
tinate mouse macrophages in vitro (Table I). (b) When immune lymphoid ceils 
were treated with ALG and washed exhaustively before transfer, they failed to 
protect (Fig. 6). The immunosuppressive effect of ALG is judged therefore to 
result from its action on donor cells rather than the phagocytes of the recipient. 
(c) ALG did not interfere significantly with established resistance in recently 
infected mice.  Since  resistance  in  early convalescence is  due  to  the  highly 
activated macrophages  which persist  for some  time  after  the  infection has 
been overcome (1), the absence of any depressing effect of ALG at the height 
of  established  immunity indicates  that  it  has  little  if  any  antimacrophage 
activity in vivo. Since bacteria are cleared rapidly from the blood, it is obvious 
that the cells which ingest them are accessible  to ALG, so that the question of 
penetration need not be raised. (d)  Finally, it will be reported in a subsequent 
paper that the preparations of ALG used in these experiments did not depress 
the monocyte count in the peripheral blood. 
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owes its  immunosuppressive activity in  the  system studied  to its  ability  to 
neutralize the immunologically committed cells in suspensions prepared from 
immune spleens.  Its  capacity in  this  regard is  very impressive.  The rabbits 
which  provided the  antiserum were in no sense hyperimmunized. They had 
received only two injections of 109 thymocytes. The ALG fractions prepared 
from these  animals  9  months  after immunization were  as potent in  lymph- 
agglutination  and immunosuppressive  activity as  were  those obtained 2  wk 
after immunization. Their capacity to neutralize immune lymphoid cells was 
greater  than  would  be  deduced  from  their  agglutinating  activity.  A  sharp 
end point, represented by the lowest dilution containing cell aggregates,  was 
obtained in agglutination tests at a  dilution of 1:128 (=  75 #g protein/ml), 
and a cell concentration of 1 X  107/ml.  The same preparation at a dilution of 
1:80  (120  #g  protein/ml)  completely suppressed  the  committed  cells  in  a 
population of 2  X  108 spleen cells,  of which the great majority were lympho- 
cytes. Since 20 times as many cells were used to measure immunosuppressive 
activity, it follows that  this  test  is  more sensitive  than  agglutination  by  a 
factor of 12. 
A  further indication  of the  immunosuppressive potency of ALG was  the 
finding that the specific antibody in a single dose of 0.1 ml (0.97 mg total IgG) 
suppressed most  of the protective activity associated with immune cells in- 
jected 24 hr later (Fig. 4). During the interval, considerable opportunity must 
have  existed for  antibody molecules  to  be  removed from  circulation.  Even 
when allowance is made for the fact that extravascular lymphocytes may be 
inaccessible to ALG, it is still surprising that so much activity persisted in the 
circulation after 24  hr.  There are  about  l0  T lymphocytes in  circulation and 
many times this number are delivered to the circulation from the thoracic duct 
lymph alone (12). It must be reasoned that very few antibody molecules are 
needed to interfere with the function of committed cells and that the innumer- 
able cells which line the vasculature cannot be very rich in the antigenic deter- 
minants represented on the lymphocytes. 
Allusion has been made repeatedly to the uncharacterized cells in the spleens 
of immune donors against which the activity of ALG was measured in these 
studies. One of the major unsolved problems of cellular immunology concerns 
identity and properties of the cells which mediate specific cellular hypersen- 
sitivity and the associated antibacterial immunity which arises in certain infec- 
tions. According to the conventional view, the immunocompetent cells which 
engage in an immune response undergo blast transformation and a succession 
of divisions from which come committed cells with the morphology of lympho- 
cytes (13, 14). The question of whether or not these cells engage in the synthesis 
of immunoglobulin remains unanswered because no antibody has been found 
in serum or cells which will passively sensitize recipients (3) or protect them 
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them to perform both of these functions. To do so they must be alive (2)  (Fig. 
2),  and be metabolically intact if they are to perform efficiently (2).  It seems, 
therefore,  that  the  immunosuppressive  activity  of  ALG  depends  upon  its 
capacity  to  interrupt  the  metabolism  of  immunologically committed cells. 
Mitomycin C does not appear to be capable of this, since it was shown in the 
previous paper (2)  that a  given number of immune cells produced a  low but 
persisting background of resistance which did not increase with time, suggesting 
that mitomycin C  interferes with cell division without disturbing other im- 
portant metabolic activities. Whatever ALG does to lymphoid cells, it does it 
with greater efficiency than mitomycin C. It is comparable, in fact, with heat at 
56°C (Fig. 2) in its ability to abolish the immunological capabilities of passively 
transferred cells. This suggests that ALG-treated cells may actually be killed. 
There was no evidence, however, that they are lysed by the complement levels 
present in mouse serum. Opsonization and subsequent phagocytosis would be 
an equally effective way to dispose of sensitized cells. A subsequent pape  rl will 
present evidence that destruction by phagocytosis is  a  major factor in  the 
immunosuppression  achieved  with ALG. 
This raises an important point. It has long been argued that ALG does not 
interfere with an ongoing immune response (11) or with a secondary immune 
response (10).  Although the evidence for this is not good enough to sustain a 
compelling  argument,  it  has  been  concluded  that  ALG  is  inactive  against 
immunologically committed cells and must therefore owe its immunosuppres- 
sire activity to its effect on uncommitted cells before they become engaged in 
an immune response (11). In other words, the immunocompetent precursors are 
the  cells  which  are  violated by this  immunosuppressant.  If  we  regard  the 
cellular mediators of delayed-type hypersensitivity and acquired anti-Listeria 
resistance as the cellular equivalents of specific antibody, these immunologically 
committed cells are the counter parts of the plasma cells which are said to be 
unaffected by ALG. Since it is clear from the present studies that the mediators 
of cellular immunity are highly vulnerable to attack by ALG, we must con- 
elude, either that cells committed to antibody production and those committed 
to the mediation of cellular hypersensitivity differ in their sensitivity to ALG, or 
that the evidence is misleading. 
The question seems to have been resolved by experiments reported in this 
paper. When no precautions were taken to avoid a source of artifact, it seemed 
that immune lymphoid cells  could be  inactivated in the  spleen by treating 
donors with ALG for 24 hr prior to cell transfer. This finding could not be 
reconciled with the fact that 10 days of treatment with ALG did not wholly 
suppress  the memory of a  previous infection in actively immunized animals 
(Fig. 8).  The experiment was therefore repeated with modifications which led 
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to a more easily interpreted result. When care was taken to leach from spleen 
slices what ALG was still present in the organ,  presumably in blood vessels, 
the immune cells within the spleen were still fully protective when dispersed 
and injected into normal recipients.  Since immune lymphoid cells which had 
been treated with ALG in vitro could not be reactivated by repeated washing 
(Fig.  6),  it follows that  similar  treatment  of spleen slices would  not  restore 
activity to cells which had been exposed to ALG in vivo. Since cells were still 
active when taken from donors which had been treated with ALG in a dose 40- 
fold greater than that required to abolish the protective activity in 2  X  108 
spleens in vitro, it follows that ALG does not have ready access to extravascular 
cells. This finding accords with the conclusion of Denman et al. (4) who claimed, 
from fluorescent antibody studies, that extravascular lymphocytes within the 
lymphoreticular tissues are not easily accessible to ALG. 
This means that ALG can depress immune mechanisms which are mediated 
by  committed  cells  only if  the  cells  recirculate.  This  would  bring  them  in 
contact not only with ALG but also with the phagocytic elements of the retic- 
uloendothelial  system.  If  the  immunosuppressive effects of ALG are due to 
deletion of cells by phagocytosis, there is an easy explanation of why it takes 
many days to ablate an existing state of immunological reactivity. The time 
taken to eliminate all reactive cells would become a function of their recircula- 
tion time. It is known that the memory cells which engage in a secondary anti- 
body response enter the circulation (15). There is every reason to believe that 
those which are concerned in cell-mediated reactions also circulate. 
From  these  considerations  it  seems  that  observed differences in  the  sus- 
ceptibility of various states of immunity to suppression by ALG are not ex- 
plained by differing susceptibilities of the cells involved, but by their anatomical 
location. All cells within the lymphoid series may be equally  susceptible,  but 
not equally accessible to ALG. 
SUMMARY 
The specificity of anti-lymphocyte globulin (ALG) has been used to analyze 
an  immune  mechanism  which  is  mediated  by  immunologically  committed 
lymphoid cells to the  apparent exclusion of humoral  antibody.  Rabbit  anti- 
mouse lymphocyte globulin completely suppressed the immunity which can be 
passively transferred with  Listeria-immune lymphoid cells from actively in- 
fected donors. When prospective donors were given a single dose of 1.0 mg of 
ALG,  it  remained  active  against  immune  lymphoid  cells  transferred  24  hr 
later; yet immune cells in the spleens of donors could not be inactivated in situ 
by even larger doses of ALG given 24 hr prior to cell harvest. In keeping with 
this finding, the immunity to reinfection with Listeria was not suppressed by a 
single  dose of ALG,  indicating  that  the  immunologically active cells in  the 
spleen  are  not  accessible  to intravenously administered ALG.  On  the  other G.  B.  MACKANESS AND  WILLIAM  C.  HILL  1011 
hand,  protracted treatment with ALG did  abolish most of the memory of a 
previous infection in intact animals. From this and other evidence, it was con- 
cluded that immunologically committed cells are vulnerable to attack by ALG 
only if they circulate. While in circulation, they make contact both with ALG 
and the phagocytic elements of the reticuloendothelial system which appear to 
be responsible for their destruction. 
Four lines of evidence indicated that the suppression of anti-Listeria resist- 
ance  with  ALG depends upon destruction of immune lymphoid cells and not 
to any action it has on host macrophages. It is possible to infer from this that 
immunity to L.  monocytogenes  depends upon  a  two cell system in which  the 
donor lymphoid cells provide the immunological reactivity to the organism and 
recipient  macrophages  provide  the  mechanism  through  which  resistance  is 
expressed. Accompanying papers provide additional support for this view, and 
reasons for believing that delayed-type hypersensitivity and acquired cellular 
resistance are mediated by the same population of immunologically committed 
lymphoid cells. 
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